3649 results for «414»
3649 results
Align for the future with case-based discussions on next generation balloon expandable transcatheter heart valve technology
16 May 2024 – From EuroPCR 2024
Join this EuroPCR 2024 session to delve into the cutting-edge innovations and techniques shaping transcatheter heart valve interventions. Witness firsthand the versatility of the Myval Octacor THV platform, navigating through challenging scenarios with ease, explore the significance of lifetime patient management in TAVI, unveiling the novel...
Treatment strategies of calcified lesions
14 May 2024 – From EuroPCR 2024
This session, comprising selected EuroPCR 2024 Abstract submissions, explores various treatment strategies for calcified coronary lesions. It includes presentations and discussions on the invasive evaluation of coronary artery compliance modification after intracoronary lithotripsy, a retrospective comparison of rotational atherectomy in NSTE-ACS and stable angina patients, the...
Tough calls during complex PCI
14 May 2024 – From EuroPCR 2024
This joint session with India Live focuses on understanding the reasons for potential failures during complex PCI and strategies to overcome them. It features case presentations and discussions on successfully managing challenging scenarios, including cases where the operator had previously failed, as well as cases where...
Challenging situations and complications in patients with ACS and acute heart failure undergoing PCI
14 May 2024 – From EuroPCR 2024
This session, with the collaboration of various national societies, focuses on understanding different approaches and techniques for managing challenging situations and complications in patients with ACS and acute heart failure undergoing PCI. It covers the prompt recognition of potential periprocedural complications, various management strategies for PCI...
Innvolution Healthcare reports one-year findings from the ALCHEMY study evaluating Eternia in 1000 patients at EuroPCR 2026
27 May 2026
Four-Year Outcomes from the EVOLUT Low Risk Trial
26 Oct 2023
Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)
Author
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: primary biomarker analysis from the EARLY TAVR Trial
01 Apr 2025
Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.
Author
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
